IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Aug 6, 2021 · 10-Q · 37 days after period end · 0000950170-21-001015
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Net Income | -$21.75M | -$17.61M | -$9.06M | -$3.11M |
| EPS Diluted | -$0.74 | -$0.60 | -$0.57 | -$0.93 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 6, 2021 · 37 d after period end
